Vasso Apostolopoulos

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/855613/publications.pdf Version: 2024-02-01

		29994	43802
256	11,514	54	91
papers	citations	h-index	g-index
263	263	263	13066
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Neuroinflammation as an etiological trigger for depression comorbid with inflammatory bowel disease. Journal of Neuroinflammation, 2022, 19, 4.	3.1	34
2	Omicron variant (B.1.1.529) of SARS-CoV-2: Threat for the elderly?. Maturitas, 2022, 158, 78-81.	1.0	40
3	The race for a COVID-19 vaccine: where are we up to?. Expert Review of Vaccines, 2022, 21, 355-376.	2.0	11
4	The Role of Bioactive Compounds from Dietary Spices in the Management of Metabolic Syndrome: An Overview. Nutrients, 2022, 14, 175.	1.7	8
5	A Brief, Daily, Online Mental Health and Well-being Intervention for University Staff During the COVID-19 Pandemic: Program Description and Outcomes Using a Mixed Methods Design. JMIR Formative Research, 2022, 6, e35776.	0.7	3
6	Global impact of delta plus variant and vaccination. Expert Review of Vaccines, 2022, 21, 597-600.	2.0	41
7	ls Booster Dose Strategy Sufficient for Omicron Variant of SARS-CoV-2?. Vaccines, 2022, 10, 367.	2.1	38
8	The Human Myelin Proteome and Sub-Metalloproteome Interaction Map: Relevance to Myelin-Related Neurological Diseases. Brain Sciences, 2022, 12, 434.	1.1	2
9	Divergent Adaptations in Autonomic Nerve Activity and Neuroimmune Signaling Associated With the Severity of Inflammation in Chronic Colitis. Inflammatory Bowel Diseases, 2022, 28, 1229-1243.	0.9	8
10	Discovery of a new generation of angiotensin receptor blocking drugs: Receptor mechanisms and in silico binding to enzymes relevant to SARS-CoV-2. Computational and Structural Biotechnology Journal, 2022, 20, 2091-2111.	1.9	18
11	Replicating Viral Vector-Based Vaccines for COVID-19: Potential Avenue in Vaccination Arena. Viruses, 2022, 14, 759.	1.5	41
12	A global picture: therapeutic perspectives for COVID-19. Immunotherapy, 2022, 14, 351-371.	1.0	56
13	Assessment of Yeasts as Potential Probiotics: A Review of Gastrointestinal Tract Conditions and Investigation Methods. Journal of Fungi (Basel, Switzerland), 2022, 8, 365.	1.5	14
14	Identification and Effects of Skim Milk-Derived Bioactive Antihypertensive Peptides. Biologics, 2022, 2, 1-14.	2.3	1
15	2-Deoxy-D-Glucose and its Derivatives for the COVID-19 Treatment: An Update. Frontiers in Pharmacology, 2022, 13, 899633.	1.6	19
16	<i>Chlamydia trachomatis</i> : quest for an eye-opening vaccine breakthrough. Expert Review of Vaccines, 2022, 21, 771-781.	2.0	5
17	Exercise in the management of multiple sclerosis. , 2022, , 163-173.		1
18	Understanding the Driving Forces That Trigger Mutations in SARS-CoV-2: Mutational Energetics and the Role of Arginine Blockers in COVID-19 Therapy. Viruses, 2022, 14, 1029.	1.5	17

#	Article	IF	CITATIONS
19	Rare monkeypox: Is it really a threat to the elderly?. Maturitas, 2022, 163, 90-91.	1.0	11
20	New Advances in Short Peptides: Looking Forward. Molecules, 2022, 27, 3635.	1.7	9
21	Therapeutics to tackle Omicron outbreak. Immunotherapy, 2022, 14, 833-838.	1.0	22
22	MUC1 expressing tumor growth was retarded after human mucin 1 (MUC1) plasmid DNA immunization. International Journal of Immunopathology and Pharmacology, 2022, 36, 039463202211123.	1.0	0
23	Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review. Molecules, 2022, 27, 4315.	1.7	56
24	Reply to the letter â€~ <i>Effectiveness of COVID-19 vaccines against Omicron variant'</i> . Immunotherapy, 2022, 14, 905-908.	1.0	3
25	Potent CCR3 Receptor Antagonist, SB328437, Suppresses Colonic Eosinophil Chemotaxis and Inflammation in the Winnie Murine Model of Spontaneous Chronic Colitis. International Journal of Molecular Sciences, 2022, 23, 7780.	1.8	7
26	Immune-boosting role of vitamins D, C, E, zinc, selenium and omega-3 fatty acids: Could they help against COVID-19?. Maturitas, 2021, 143, 1-9.	1.0	263
27	The effects of photobiomodulation on human dermal fibroblasts in vitro: A systematic review. Journal of Photochemistry and Photobiology B: Biology, 2021, 214, 112100.	1.7	19
28	Be well: A potential role for vitamin B in COVID-19. Maturitas, 2021, 144, 108-111.	1.0	108
29	The Effect of Gum Arabic (Acacia senegal) on Cardiovascular Risk Factors and Gastrointestinal Symptoms in Adults at Risk of Metabolic Syndrome: A Randomized Clinical Trial. Nutrients, 2021, 13, 194.	1.7	16
30	Can SARS-CoV-2 Virus Use Multiple Receptors to Enter Host Cells?. International Journal of Molecular Sciences, 2021, 22, 992.	1.8	106
31	A Global Review on Short Peptides: Frontiers and Perspectives. Molecules, 2021, 26, 430.	1.7	190
32	Immunomodulatory Effects of Dietary Polyphenols. Nutrients, 2021, 13, 728.	1.7	106
33	Mechanisms of Cisplatin-Induced Acute Kidney Injury: Pathological Mechanisms, Pharmacological Interventions, and Genetic Mitigations. Cancers, 2021, 13, 1572.	1.7	135
34	Dual targeting of Toll-like receptor 4 and angiotensin-converting enzyme 2: aÂproposed approach to SARS-CoV-2 treatment. Future Microbiology, 2021, 16, 205-209.	1.0	23
35	Anti-cancer effects of polyphenol-rich sugarcane extract. PLoS ONE, 2021, 16, e0247492.	1.1	21
36	Anti-Cancer Effects of Carnosine—A Dipeptide Molecule. Molecules, 2021, 26, 1644.	1.7	16

VASSO APOSTOLOPOULOS

#	Article	IF	CITATIONS
37	COVID-19 Vaccines in the Pipeline, Are Antibodies Adequate?. Vaccines, 2021, 9, 241.	2.1	9
38	The Effects of Bariatric Surgery on Vitamin B Status and Mental Health. Nutrients, 2021, 13, 1383.	1.7	16
39	Nutritional Interventions for COVID-19: A Role for Carnosine?. Nutrients, 2021, 13, 1463.	1.7	9
40	The emergence of new strains of SARS-CoV-2. What does it mean for COVID-19 vaccines?. Expert Review of Vaccines, 2021, 20, 635-638.	2.0	66
41	Immune to addiction: how immunotherapies can be used to combat methamphetamine addiction. Expert Review of Vaccines, 2021, 20, 707-715.	2.0	8
42	A Veterinary Vaccine for SARS-CoV-2: The First COVID-19 Vaccine for Animals. Vaccines, 2021, 9, 631.	2.1	40
43	Computational Chemistry to Repurposing Drugs for the Control of COVID-19. Biologics, 2021, 1, 111-128.	2.3	8
44	Is COVID-19 the worst pandemic?. Maturitas, 2021, 149, 56-58.	1.0	71
45	Receptor Interactions of Angiotensin II and Angiotensin Receptor Blockers—Relevance to COVID-19. Biomolecules, 2021, 11, 979.	1.8	15
46	Mucormycosis – An opportunistic infection in the aged immunocompromised individual: A reason for concern in COVID-19. Maturitas, 2021, 154, 58-61.	1.0	32
47	The effect of low-level red and near-infrared photobiomodulation on pain and function in tendinopathy: a systematic review and meta-analysis of randomized control trials. BMC Sports Science, Medicine and Rehabilitation, 2021, 13, 91.	0.7	7
48	Immunomodulatory Properties of Polyphenol-Rich Sugarcane Extract on Human Monocytes. Biologics, 2021, 1, 211-221.	2.3	2
49	DNA vaccines for SARS-CoV-2: toward third-generation vaccination era. Expert Review of Vaccines, 2021, 20, 1549-1560.	2.0	60
50	From Angiotensin II to Cyclic Peptides and Angiotensin Receptor Blockers (ARBs): Perspectives of ARBs in COVID-19 Therapy. Molecules, 2021, 26, 618.	1.7	15
51	Nucleic Acid Vaccines for COVID-19: A Paradigm Shift in the Vaccine Development Arena. Biologics, 2021, 1, 337-356.	2.3	58
52	Novel Approaches in the Immunotherapy of Multiple Sclerosis: Cyclization of Myelin Epitope Peptides and Conjugation with Mannan. Brain Sciences, 2021, 11, 1583.	1.1	5
53	Immune Modulatory Effects of Probiotic Streptococcus thermophilus on Human Monocytes. Biologics, 2021, 1, 396-415.	2.3	14
54	Myelin Peptide–Mannan Conjugate Multiple Sclerosis Vaccines: Conjugation Efficacy and Stability of Vaccine Ingredient. Vaccines, 2021, 9, 1456.	2.1	6

#	Article	IF	CITATIONS
55	Polarized light therapy: Shining a light on the mechanism underlying its immunomodulatory effects. Journal of Biophotonics, 2020, 13, e201960177.	1.1	12
56	The potential actions of angiotensin onverting enzyme II (ACE2) activator diminazene aceturate (DIZE) in various diseases. Clinical and Experimental Pharmacology and Physiology, 2020, 47, 751-758.	0.9	74
57	Assessment of Sodium Knowledge and Urinary Sodium Excretion among Regions of the United Arab Emirates: A Cross-Sectional Study. Nutrients, 2020, 12, 2747.	1.7	7
58	The potential application of probiotics and prebiotics for the prevention and treatment of COVID-19. Npj Science of Food, 2020, 4, 17.	2.5	135
59	The role of D-dimer in relation to the clinical course of patients with COVID-19. Acta Biochimica Et Biophysica Sinica, 2020, 53, 119-120.	0.9	3
60	Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab. Brain Sciences, 2020, 10, 758.	1.1	55
61	Bioimaging of C2C12 Muscle Myoblasts Using Fluorescent Carbon Quantum Dots Synthesized from Bread. Nanomaterials, 2020, 10, 1575.	1.9	5
62	The Use of Electrochemical Voltammetric Techniques and High-Pressure Liquid Chromatography to Evaluate Conjugation Efficiency of Multiple Sclerosis Peptide-Carrier Conjugates. Brain Sciences, 2020, 10, 577.	1.1	6
63	The Anti-Inflammatory Effect of Taurine on Cardiovascular Disease. Nutrients, 2020, 12, 2847.	1.7	64
64	Dendritic Cells and Myeloid Derived Suppressor Cells Fully Responsive to Stimulation via Toll-Like Receptor 4 Are Rapidly Induced from Bone-Marrow Cells by Granulocyte-Macrophage Colony-Stimulating Factor. Vaccines, 2020, 8, 522.	2.1	8
65	Leucocyte-Rich Platelet-Rich Plasma Enhances Fibroblast and Extracellular Matrix Activity: Implications in Wound Healing. International Journal of Molecular Sciences, 2020, 21, 6519.	1.8	15
66	Vaccine development against methamphetamine drug addiction. Expert Review of Vaccines, 2020, 19, 1105-1114.	2.0	15
67	Why METH users are at high risk of fatality due to COVID-19 infection?. Expert Review of Vaccines, 2020, 19, 1101-1103.	2.0	13
68	Advances in Multiple Sclerosis Research–Series I. Brain Sciences, 2020, 10, 795.	1.1	5
69	The Long Road of Immunotherapeutics against Multiple Sclerosis. Brain Sciences, 2020, 10, 288.	1.1	7
70	Could DIZE be the answer to COVID-19?. Maturitas, 2020, 140, 83-84.	1.0	12
71	Streptococcus thermophilus ST285 Alters Pro-Inflammatory to Anti-Inflammatory Cytokine Secretion against Multiple Sclerosis Peptide in Mice. Brain Sciences, 2020, 10, 126.	1.1	40
72	Good, better, best? The effects of polarization on photobiomodulation therapy. Journal of Biophotonics, 2020, 13, e201960230.	1.1	18

VASSO APOSTOLOPOULOS

#	Article	IF	CITATIONS
73	Streptococcus thermophilus alters the expression of genes associated with innate and adaptive immunity in human peripheral blood mononuclear cells. PLoS ONE, 2020, 15, e0228531.	1.1	23
74	Polyphenol Rich Sugar Cane Extract Inhibits Bacterial Growth. Prilozi - Makedonska Akademija Na Naukite I Umetnostite Oddelenie Za Medicinski Nauki, 2020, 41, 49-57.	0.2	4
75	The Complex Interaction between the Tumor Micro-Environment and Immune Checkpoints in Breast Cancers, 2019, 11, 1205.	1.7	57
76	Anti-Tumor Effects of Vitamin B2, B6 and B9 in Promonocytic Lymphoma Cells. International Journal of Molecular Sciences, 2019, 20, 3763.	1.8	40
77	Vitamin B1, B2, B3, B5, and B6 and theÂlmmune System. , 2019, , 115-125.		32
78	Cancer Vaccines: Research and Applications. Cancers, 2019, 11, 1041.	1.7	19
79	Vitamin B12, Folic Acid, and the Immune System. , 2019, , 103-114.		18
80	Vitamin D enzymes (CYP27A1, CYP27B1, and CYP24A1) and receptor expression in non-melanoma skin cancer. Acta Biochimica Et Biophysica Sinica, 2019, 51, 444-447.	0.9	10
81	Oxaliplatin Treatment Alters Systemic Immune Responses. BioMed Research International, 2019, 2019, 1-15.	0.9	35
82	Eosinophils in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2019, 25, 1140-1151.	0.9	47
83	Immunomodulatory effects of probiotics: Can they be used to treat allergies and autoimmune diseases?. Maturitas, 2019, 119, 25-38.	1.0	82
84	Methamphetamine and its immune-modulating effects. Maturitas, 2019, 121, 13-21.	1.0	51
85	Role of the Nervous System in Tumor Angiogenesis. Cancer Microenvironment, 2018, 11, 1-11.	3.1	33
86	Protective efficacy of a plasmid DNA vaccine against transgene-specific tumors by Th1 cellular immune responses after intradermal injection. Cellular Immunology, 2018, 329, 17-26.	1.4	11
87	The Onset and Progression of Chronic Colitis Parallels Increased Mucosal Serotonin Release via Enterochromaffin Cell Hyperplasia and Downregulation of the Serotonin Reuptake Transporter. Inflammatory Bowel Diseases, 2018, 24, 1021-1034.	0.9	22
88	Immune-based therapies for metastatic prostate cancer: an update. Immunotherapy, 2018, 10, 283-298.	1.0	9
89	PD-1/PD-L1 in disease. Immunotherapy, 2018, 10, 149-160.	1.0	90
90	Crosstalk between cancer and the neuro-immune system. Journal of Neuroimmunology, 2018, 315, 15-23.	1.1	48

6

#	Article	IF	CITATIONS
91	Cyclization of PLP139-151 peptide reduces its encephalitogenic potential in experimental autoimmune encephalomyelitis. Bioorganic and Medicinal Chemistry, 2018, 26, 2221-2228.	1.4	7
92	Mannosylated T/Tn with Freund's adjuvant induces cellular immunity. International Journal of Immunopathology and Pharmacology, 2018, 31, 039463201774250.	1.0	5
93	Effects of fermented skim milk drink by <i>Kluyveromyces marxianus </i> <scp>LAF</scp> 4 coâ€cultured with lactic acid bacteria to release angiotensinâ€converting enzyme inhibitory activities. International Journal of Dairy Technology, 2018, 71, 130-140.	1.3	13
94	Yeast based spreads improve anxiety and stress. Journal of Functional Foods, 2018, 40, 471-476.	1.6	13
95	Processing and sensory characteristics of a fermented lowâ€fat skim milk drink containing bioactive antihypertensive peptides, a functional milk product. International Journal of Dairy Technology, 2018, 71, 230-239.	1.3	12
96	B Vitamins and Ageing. Sub-Cellular Biochemistry, 2018, 90, 451-470.	1.0	34
97	Design of Linear and Cyclic Mutant Analogues of Dirucotide Peptide (MBP82–98) against Multiple Sclerosis: Conformational and Binding Studies to MHC Class II. Brain Sciences, 2018, 8, 213.	1.1	4
98	Effects of platelet-rich plasma and platelet-poor plasma on human dermal fibroblasts. Maturitas, 2018, 117, 34-44.	1.0	24
99	Immunomodulatory effects of Streptococcus thermophilus on U937 monocyte cell cultures. Journal of Functional Foods, 2018, 49, 241-249.	1.6	17
100	Physical activity and breast cancer survivors: Importance of adherence, motivational interviewing and psychological health. Maturitas, 2018, 116, 66-72.	1.0	61
101	Anti-hypertensive peptides released from milk proteins by probiotics. Maturitas, 2018, 115, 103-109.	1.0	45
102	Role of the nervous system in cancer metastasis. Journal of Experimental and Clinical Cancer Research, 2018, 37, 5.	3.5	95
103	Therapeutic applications of polarized light: Tissue healing and immunomodulatory effects. Maturitas, 2018, 116, 11-17.	1.0	23
104	Editorial: Multiple Sclerosis: Pathogenesis and Therapeutics. Medicinal Chemistry, 2018, 14, 104-105.	0.7	20
105	Oxaliplatin-induced changes in microbiota, TLR4+ cells and enhanced HMGB1 expression in the murine colon. PLoS ONE, 2018, 13, e0198359.	1.1	33
106	Progression of carotid artery disease could stratify a risk of coronary artery disease patients with type 2 diabetes. Acta Biochimica Et Biophysica Sinica, 2018, 51, 120-122.	0.9	6
107	Design, synthesis and evaluation of an anthraquinone derivative conjugated to myelin basic protein immunodominant (MBP85-99) epitope: Towards selective immunosuppression. European Journal of Medicinal Chemistry, 2018, 143, 621-631.	2.6	5
108	Is there a Link between Vitamin B and Multiple Sclerosis?. Medicinal Chemistry, 2018, 14, 170-180.	0.7	42

#	Article	IF	CITATIONS
109	Transdermal Delivery of AT1 Receptor Antagonists Reduce Blood Pressure and Reveal a Vasodilatory Effect on Kidney Blood Vessels. Current Molecular Pharmacology, 2018, 11, 226-236.	0.7	3
110	Predicting sediment formation in ultra high temperature-treated whole and skim milkÂusing attenuated total reflectance-Fourier transform infrared spectroscopy. International Dairy Journal, 2017, 74, 39-48.	1.5	24
111	Prognostic implications of myocardial perfusion imaging and coronary calcium score in a Macedonian cohort of asymptomatic patients with type 2 diabetes. Diabetes and Vascular Disease Research, 2017, 14, 285-294.	0.9	7
112	Elevated serum interleukin-5 levels in severe chronic obstructive pulmonary disease. Acta Biochimica Et Biophysica Sinica, 2017, 49, 560-563.	0.9	8
113	Breast cancer and exercise: The role of adiposity and immune markers. Maturitas, 2017, 105, 16-22.	1.0	32
114	The mechanisms tumor cells utilize to evade the host's immune system. Maturitas, 2017, 105, 8-15.	1.0	48
115	Resveratrol alleviates oxidative damage in enteric neurons and associated gastrointestinal dysfunction caused by chemotherapeutic agent oxaliplatin. Maturitas, 2017, 105, 100-106.	1.0	17
116	Cyclic MOG 35 – 55 ameliorates clinical and neuropathological features of experimental autoimmune encephalomyelitis. Bioorganic and Medicinal Chemistry, 2017, 25, 4163-4174.	1.4	11
117	Unus pro omnibus, omnes pro uno: A novel, evidence-based, unifying theory for the pathogenesis of endometriosis. Medical Hypotheses, 2017, 103, 10-20.	0.8	177
118	Methamphetamine: Effects on the brain, gut and immune system. Pharmacological Research, 2017, 120, 60-67.	3.1	143
119	The effects of vitamin B on the immune/cytokine network and their involvement in depression. Maturitas, 2017, 96, 58-71.	1.0	104
120	Fourier transform infrared spectroscopy analysis of physicochemical changes in UHT milk during accelerated storage. International Dairy Journal, 2017, 66, 99-107.	1.5	58
121	Electrophoretic characterization of protein interactions suggesting limited feasibility of accelerated shelf-life testing of ultra-high temperature milk. Journal of Dairy Science, 2017, 100, 76-88.	1.4	18
122	Exercise and mental health. Maturitas, 2017, 106, 48-56.	1.0	523
123	Alamandine reverses hyperhomocysteinemiaâ€induced vascular dysfunction via <scp>PKA</scp> â€dependent mechanisms. Cardiovascular Therapeutics, 2017, 35, e12306.	1.1	32
124	CRP and fibrinogen imply clinical outcome of patients with Type-2 diabetes and coronary artery disease. Acta Biochimica Et Biophysica Sinica, 2017, 49, 284-285.	0.9	10
125	Exercise in Menopausal Women. , 2017, , 285-307.		2
126	Cyclic citrullinated MBP87–99 peptide stimulates T cell responses: Implications in triggering disease. Bioorganic and Medicinal Chemistry, 2017, 25, 528-538.	1.4	16

#	Article	IF	CITATIONS
127	Cellular Mucins: Targets for Immunotherapy. Critical Reviews in Immunology, 2017, 37, 421-437.	1.0	57
128	Multiple Sclerosis: Immunopathology and Treatment Update. Brain Sciences, 2017, 7, 78.	1.1	197
129	Design and Synthesis of Non-Peptide Mimetics Mapping the Immunodominant Myelin Basic Protein (MBP83–96) Epitope to Function as T-Cell Receptor Antagonists. International Journal of Molecular Sciences, 2017, 18, 1215.	1.8	14
130	Vaccine Delivery Methods into the Future. Vaccines, 2016, 4, 9.	2.1	24
131	Eosinophils in Cancer: Favourable or Unfavourable?. Current Medicinal Chemistry, 2016, 23, 650-666.	1.2	128
132	Proteolytic and angiotensin-converting enzyme-inhibitory activities of selected probiotic bacteria. International Journal of Food Science and Technology, 2016, 51, 865-874.	1.3	10
133	The complex immunological and inflammatory network of adipose tissue in obesity. Molecular Nutrition and Food Research, 2016, 60, 43-57.	1.5	139
134	The Effects of Hormonal Therapy and Exercise on Bone Turnover in Postmenopausal Women: A Randomised Double-Blind Pilot Study. Prilozi - Makedonska Akademija Na Naukite I Umetnostite Oddelenie Za Medicinski Nauki, 2016, 37, 23-32.	0.2	3
135	Hormone Therapy Reduces Bone Resorption but not Bone Formation in Postmenopausal Athletes. Prilozi - Makedonska Akademija Na Naukite I Umetnostite Oddelenie Za Medicinski Nauki, 2016, 37, 15-21.	0.2	4
136	MUC1 immunotherapy against a metastatic mammary adenocarcinoma model: Importance of IFN-gamma. Prilozi - Makedonska Akademija Na Naukite I Umetnostite Oddelenie Za Medicinski Nauki, 2016, 37, 15-25.	0.2	4
137	Vaccine delivery by penetratin: mechanism of antigen presentation by dendritic cells. Immunologic Research, 2016, 64, 887-900.	1.3	23
138	Angiotensin (1-7) and Alamandine: Similarities and differences. Pharmacological Research, 2016, 111, 820-826.	3.1	51
139	Cognitive decline: A vitamin B perspective. Maturitas, 2016, 93, 108-113.	1.0	55
140	T/Tn immunotherapy avoiding immune deviation. International Journal of Immunopathology and Pharmacology, 2016, 29, 812-817.	1.0	7
141	Alteration of early dendritic cell activation by cancer cell lines predisposes immunosuppression, which cannot be reversed by TLR4 stimulation. Acta Biochimica Et Biophysica Sinica, 2016, 48, 1101-1111.	0.9	2
142	Leukocyte populations and IL-6 in the tumor microenvironment of an orthotopic colorectal cancer model. Acta Biochimica Et Biophysica Sinica, 2016, 48, 334-341.	0.9	17
143	An Effective Model for Prevention and Management of Type 2 Diabetes. Qualitative Health Research, 2016, 26, 603-612.	1.0	4
144	The Effects of Vitamin B in Depression. Current Medicinal Chemistry, 2016, 23, 4317-4337.	1.2	112

#	Article	IF	CITATIONS
145	Mannosylated Linear and Cyclic Single Amino Acid Mutant Peptides Using a Small 10 Amino Acid Linker Constitute Promising Candidates Against Multiple Sclerosis. Frontiers in Immunology, 2015, 6, 136.	2.2	13
146	Inflammatory biomarkers: impact for diabetes and diabetic vascular disease. Acta Biochimica Et Biophysica Sinica, 2015, 47, 1029-1031.	0.9	14
147	Effects of active immunisation with myelin basic protein and myelin-derived altered peptide ligand on pain hypersensitivity and neuroinflammation. Journal of Neuroimmunology, 2015, 286, 59-70.	1.1	12
148	Conjugation of a peptide to mannan and its confirmation by tricine sodium dodecyl sulfate–polyacrylamide gel electrophoresis. Analytical Biochemistry, 2015, 485, 43-45.	1.1	16
149	Properties of myelin altered peptide ligand cyclo(87-99)(Ala91,Ala96)MBP87-99 render it a promising drug lead for immunotherapy of multiple sclerosis. European Journal of Medicinal Chemistry, 2015, 101, 13-23.	2.6	17
150	Active immunization with myelin-derived altered peptide ligand reduces mechanical pain hypersensitivity following peripheral nerve injury. Journal of Neuroinflammation, 2015, 12, 28.	3.1	19
151	MUC1 (CD227): a multi-tasked molecule. Cellular and Molecular Life Sciences, 2015, 72, 4475-4500.	2.4	85
152	Mannan-conjugated myelin peptides prime non-pathogenic Th1 and Th17 cells and ameliorate experimental autoimmune encephalomyelitis. Experimental Neurology, 2015, 267, 254-267.	2.0	36
153	Calcium-Fortified Soymilk: Function and Health Benefits. Food and Nutritional Components in Focus, 2015, , 310-328.	0.1	Ο
154	Physical and immunological aspects of exercise in chronic diseases. Immunotherapy, 2014, 6, 1145-1157.	1.0	45
155	Immune responses of linear and cyclic PLP ₁₃₉₋₁₅₁ mutant peptides in SJL/J mice: peptides in their free state versus mannan conjugation. Immunotherapy, 2014, 6, 709-724.	1.0	11
156	To exercise, or, not to exercise, during menopause and beyond. Maturitas, 2014, 77, 318-323.	1.0	84
157	Dendritic cell immunotherapy: clinical outcomes. Clinical and Translational Immunology, 2014, 3, e21.	1.7	36
158	Tumor regression by CD4 T-cells primed with dendritic/tumor fusion cell vaccines. Anticancer Research, 2014, 34, 3917-24.	0.5	14
159	Cancer vaccines: looking to the future. Expert Review of Vaccines, 2013, 12, 1125-1126.	2.0	4
160	Tetraspanin <scp>CD</scp> 37 contributes to the initiation of cellular immunity by promoting dendritic cell migration. European Journal of Immunology, 2013, 43, 1208-1219.	1.6	49
161	Up to 15-year clinical follow-up of a pilot Phase III immunotherapy study in stage II breast cancer patients using oxidized mannan–MUC1. Immunotherapy, 2013, 5, 1177-1182.	1.0	92
162	Effects of Vaccination with Altered Peptide Ligand on Chronic Pain in Experimental Autoimmune Encephalomyelitis, an Animal Model of Multiple Sclerosis. Frontiers in Neurology, 2013, 4, 168.	1.1	12

#	Article	IF	CITATIONS
163	Targeting Antigens to Dendritic Cell Receptors for Vaccine Development. Journal of Drug Delivery, 2013, 2013, 1-22.	2.5	129
164	Enhanced Dendritic Cell-Mediated Antigen-Specific CD4+ T Cell Responses: IFN-Gamma Aids TLR Stimulation. Journal of Drug Delivery, 2013, 2013, 1-9.	2.5	22
165	Characterization of Blood Monocyte Phenotype in Patients With Endometrial Cancer. International Journal of Gynecological Cancer, 2012, 22, 1.	1.2	14
166	Synthesis and Immunological Evaluation of Selfâ€Assembling and Selfâ€Adjuvanting Tricomponent Glycopeptide Cancerâ€Vaccine Candidates. Chemistry - A European Journal, 2012, 18, 16540-16548.	1.7	63
167	Simultaneous immunisation with a Wilms' Tumour 1 epitope and its ubiquitin fusions results in enhanced cell mediated immunity and tumour rejection in C57BL/6 mice. Molecular Immunology, 2012, 51, 325-331.	1.0	10
168	Vaccines in clinical trials: cancer. Expert Review of Vaccines, 2011, 10, 711-712.	2.0	1
169	Whole protein and defined CD8 ⁺ and CD4 ⁺ peptides linked to penetratin targets both MHC class I and II antigen presentation pathways. Immunology and Cell Biology, 2011, 89, 904-913.	1.0	22
170	Conformational studies of immunodominant myelin basic protein 1–11 analogues using NMR and molecular modeling. Journal of Computer-Aided Molecular Design, 2011, 25, 1019-1032.	1.3	8
171	Homology modeling and molecular dynamics simulations of MUC1-9/H-2Kb complex suggest novel binding interactions. Journal of Molecular Modeling, 2011, 17, 1817-1829.	0.8	3
172	Selfâ€Adjuvanting Multicomponent Cancer Vaccine Candidates Combining Perâ€Glycosylated MUC1 Glycopeptides and the Tollâ€like Receptor 2 Agonist Pam ₃ CysSer. Angewandte Chemie - International Edition, 2011, 50, 1635-1639.	7.2	145
173	Structural elucidation of Leuprolide and its analogues in solution: insight into their bioactive conformation. Amino Acids, 2010, 39, 1147-1160.	1.2	19
174	Cell-penetrating peptides: Application in vaccine delivery. Biochimica Et Biophysica Acta: Reviews on Cancer, 2010, 1805, 25-34.	3.3	55
175	Delivery of DNA vaccines: an overview on the use of biodegradable polymeric and magnetic nanoparticles. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2010, 2, 205-218.	3.3	67
176	A Complementary Role for the Tetraspanins CD37 and Tssc6 in Cellular Immunity. Journal of Immunology, 2010, 185, 3158-3166.	0.4	44
177	Reactive Oxygen Species Level Defines Two Functionally Distinctive Stages of Inflammatory Dendritic Cell Development from Mouse Bone Marrow. Journal of Immunology, 2010, 184, 2863-2872.	0.4	58
178	Methods to measure T-cell responses. Expert Review of Vaccines, 2010, 9, 595-600.	2.0	16
179	A membrane penetrating multiple antigen peptide (MAP) incorporating ovalbumin CD8 epitope induces potent immune responses in mice. Biochimica Et Biophysica Acta - Biomembranes, 2010, 1798, 2286-2295.	1.4	20
180	A Heat Shock Protein 70-Based Vaccine with Enhanced Immunogenicity for Clinical Use. Journal of Immunology, 2010, 184, 488-496.	0.4	80

#	Article	IF	CITATIONS
181	Methods to measure vaccine immunity. Expert Review of Vaccines, 2010, 9, 545-546.	2.0	3
182	Tetraspanins CD37 and CD151 differentially regulate Ag presentation and Tâ€cell coâ€stimulation by DC. European Journal of Immunology, 2009, 39, 50-55.	1.6	64
183	Altered peptide ligands of myelin basic protein (MBP _{87–99}) conjugated to reduced mannan modulate immune responses in mice. Immunology, 2009, 128, 521-533.	2.0	42
184	Molecular basis of improved immunogenicity in DNA vaccination mediated by a mannan based carrier. Biomaterials, 2009, 30, 1389-1400.	5.7	23
185	Non-canonical anchor motif peptides bound to MHC class I induce cellular responses. Molecular Immunology, 2009, 46, 1171-1178.	1.0	7
186	Design and Synthesis of a Cyclic Double Mutant Peptide (cyclo(87â`'99)[A ⁹¹ ,A ⁹⁶]MBP _{87â^'99}) Induces Altered Responses in Mice after Conjugation to Mannan: Implications in the Immunotherapy of Multiple Sclerosis. Journal of Medicinal Chemistry, 2009, 52, 214-218.	2.9	40
187	Development of more efficient and effective DNA vaccines. Expert Review of Vaccines, 2009, 8, 1133-1134.	2.0	15
188	Peptide-based vaccines for cancer: are we choosing the right peptides?. Expert Review of Vaccines, 2009, 8, 259-260.	2.0	7
189	Non-Canonical Peptides Bound to MHC. Current Pharmaceutical Design, 2009, 15, 3274-3282.	0.9	4
190	Editorial [Hot topic: MHC and MHC-Like Molecules in the Design of Vaccines (Executive Editor: Vasso) Tj ETQqO	0 orgBT /0	Overlock 10 T
191	Delivery of antigen using a novel mannosylated dendrimer potentiates immunogenicity <i>in vitro</i> and <i>in vivo</i> . European Journal of Immunology, 2008, 38, 424-436.	1.6	139
192	Towards immunotherapeutic drugs and vaccines against multiple sclerosis. Acta Biochimica Et Biophysica Sinica, 2008, 40, 636-642.	0.9	30
193	A double mutation of MBP83–99 peptide induces IL-4 responses and antagonizes IFN-γ responses. Journal of Neuroimmunology, 2008, 200, 77-89.	1.1	34
194	Protein/peptide and DNA vaccine delivery by targeting C-type lectin receptors. Expert Review of Vaccines, 2008, 7, 1005-1018.	2.0	19
195	Design of Novel Cyclic Altered Peptide Ligands of Myelin Basic Protein MBP _{83â^'99} That Modulate Immune Responses in SJL/J Mice. Journal of Medicinal Chemistry, 2008, 51, 3971-3978.	2.9	50
196	The good, the bad and the ugly: how altered peptide ligands modulate immunity. Expert Opinion on Biological Therapy, 2008, 8, 1873-1884.	1.4	37
197	Mannosylation of mutated MBP83–99 peptides diverts immune responses from Th1 to Th2. Molecular Immunology, 2008, 45, 3661-3670.	1.0	32
198	Oxidized and reduced mannan mediated MUC1 DNA immunization induce effective anti-tumor responses. Vaccine, 2008, 26, 3827-3834.	1.7	27

#	Article	IF	CITATIONS
199	Cancer vaccines: methods for inducing immunity. Expert Review of Vaccines, 2008, 7, 861-862.	2.0	1
200	Citrullination of Linear and Cyclic Altered Peptide Ligands from Myelin Basic Protein (MBP _{87â^'99}) Epitope Elicits a Th1 Polarized Response by T Cells Isolated from Multiple Sclerosis Patients: Implications in Triggering Disease. Journal of Medicinal Chemistry, 2008, 51, 7834-7842.	2.9	47
201	Strategies used for MUC1 immunotherapy: human clinical studies. Expert Review of Vaccines, 2008, 7, 963-975.	2.0	67
202	Strategies used for MUC1 immunotherapy: preclinical studies. Expert Review of Vaccines, 2008, 7, 951-962.	2.0	43
203	The Adjuvanticity of a Mannosylated Antigen Reveals TLR4 Functionality Essential for Subset Specialization and Functional Maturation of Mouse Dendritic Cells. Journal of Immunology, 2008, 181, 2455-2464.	0.4	32
204	MHC and MHC‑like molecules: Structural perspectives on the design of molecular vaccines. Hum Vaccin, 2008, 4, 400-409.	2.4	11
205	MHC and MHC-Like Molecules: Structural Perspectives on the Design of Molecular Vaccines. Advances in Experimental Medicine and Biology, 2008, 640, 252-267.	0.8	8
206	Poly-l-lysine-coated nanoparticles: A potent delivery system to enhance DNA vaccine efficacy. Vaccine, 2007, 25, 1316-1327.	1.7	122
207	Methods of Delivery to Antigen-Presenting Cells:Â Development of New and Improved Vaccines. Molecular Pharmaceutics, 2007, 4, 1-3.	2.3	6
208	Receptor-Mediated Delivery of Antigens to Dendritic Cells:Â Anticancer Applications. Molecular Pharmaceutics, 2007, 4, 58-72.	2.3	30
209	Mannan-mediated gene delivery for cancer immunotherapy. Immunology, 2007, 120, 325-335.	2.0	52
210	Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]. Breast Cancer Research, 2006, 8, R27.	2.2	150
211	Mannan-MUC1–Pulsed Dendritic Cell Immunotherapy: A Phase I Trial in Patients with Adenocarcinoma. Clinical Cancer Research, 2006, 12, 869-877.	3.2	156
212	Pathogen recognition and development of particulate vaccines: Does size matter?. Methods, 2006, 40, 1-9.	1.9	509
213	Delivery of tumor associated antigens to antigen presenting cells using penetratin induces potent immune responses. Vaccine, 2006, 24, 3191-3202.	1.7	30
214	Penetratin tandemly linked to a CTL peptide induces anti-tumour T-cell responses via a cross-presentation pathway. Immunology, 2006, 117, 329-339.	2.0	27
215	Mannan derivatives induce phenotypic and functional maturation of mouse dendritic cells. Immunology, 2006, 118, 372-383.	2.0	120
216	Enhanced major histocompatibility complex class I binding and immune responses through anchor modification of the non-canonical tumour-associated mucin 1-8 peptide. Immunology, 2006, 119, 306-316.	2.0	20

#	Article	IF	CITATIONS
217	Structure and Design of Polycationic Carriers For Gene Delivery. Mini-Reviews in Medicinal Chemistry, 2006, 6, 1285-1298.	1.1	72
218	Round and Round we Go: Cyclic Peptides in Disease. Current Medicinal Chemistry, 2006, 13, 2221-2232.	1.2	154
219	Regulatory T-Cells: Immunomodulators in Health and Disease. Current Topics in Medicinal Chemistry, 2006, 6, 1759-1768.	1.0	7
220	Synthesis and study of the electrophoretic behavior of mannan conjugates with cyclic peptide analogue of myelin basic protein using lysine-glycine linker. Analytical Biochemistry, 2005, 347, 121-128.	1.1	28
221	Direct processing and presentation of antigen from malaria sporozoites by professional antigenâ€presenting cells in the induction of CD8 + Tâ€cell responses. Immunology and Cell Biology, 2005, 83, 307-312.	1.0	49
222	Structural and dynamic consequences of increasing repeats in a MUC1 peptide tumor antigen. Biopolymers, 2005, 77, 107-120.	1.2	10
223	Dendritic Cells: Activation and Maturation - Applications for Cancer Immunotherapy. Current Medicinal Chemistry, 2005, 12, 1783-1800.	1.2	55
224	Insights into Peptide-Based Vaccine Design for Cancer Immunotherapy. Current Medicinal Chemistry, 2005, 12, 1481-1494.	1.2	27
225	Structure and Function of the Myelin Proteins: Current Status and Perspectives in Relation to Multiple Sclerosis. Current Medicinal Chemistry, 2005, 12, 1569-1587.	1.2	37
226	Design And Synthesis of a Novel Potent Myelin Basic Protein Epitope 87â^'99 Cyclic Analogue:Â Enhanced Stability and Biological Properties of Mimics Render Them a Potentially New Class of Immunomodulatorsâ€. Journal of Medicinal Chemistry, 2005, 48, 1470-1480.	2.9	62
227	Characterization of Mice Lacking the Tetraspanin Superfamily Member CD151. Molecular and Cellular Biology, 2004, 24, 5978-5988.	1.1	167
228	Dendritic Cells Induce Immunity and Long-Lasting Protection against Blood-Stage Malaria despite an In Vitro Parasite-Induced Maturation Defect. Infection and Immunity, 2004, 72, 5331-5339.	1.0	52
229	Noncanonical peptides in complex with MHC class I. Expert Review of Vaccines, 2004, 3, 151-162.	2.0	39
230	Aspects of cancer immunotherapy. Immunology and Cell Biology, 2003, 81, 79-85.	1.0	9
231	A glycopeptide in complex with MHC class I uses the GalNAc residue as an anchor. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 15029-15034.	3.3	82
232	Structural Comparison of Allogeneic and Syngeneic T Cell Receptor–Peptide-Major Histocompatibility Complex Complexes. Journal of Experimental Medicine, 2002, 195, 1175-1186.	4.2	96
233	Antagonistic Effects of Human Cyclic MBP87-99 Altered Peptide Ligands in Experimental Allergic Encephalomyelitis and Human T-Cell Proliferation. Journal of Medicinal Chemistry, 2002, 45, 275-283.	2.9	70
234	Crystal Structure of a Non-canonical Low-affinity Peptide Complexed with MHC Class I: A New Approach For Vaccine Design. Journal of Molecular Biology, 2002, 318, 1293-1305.	2.0	65

#	Article	IF	CITATIONS
235	Crystal Structure of a Non-canonical High Affinity Peptide Complexed with MHC Class I: A Novel Use of Alternative Anchors. Journal of Molecular Biology, 2002, 318, 1307-1316.	2.0	29
236	A 16-mer peptide (RQIKIWFQNRRMKWKK) from antennapedia preferentially targets the Class I pathway. Vaccine, 2001, 19, 1397-1405.	1.7	41
237	Aldehyde-mannan antigen complexes target the MHC class I antigen-presentation pathway. European Journal of Immunology, 2000, 30, 1714-1723.	1.6	101
238	The effect of T1 and T2 cytokines on the cytotoxic T cell response to mannan-MUC1. Cancer Immunology, Immunotherapy, 2000, 48, 644-652.	2.0	24
239	MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines. Cancer Immunology, Immunotherapy, 2000, 48, 588-594.	2.0	88
240	Immunotherapy with mannan-MUC1 and IL-12 in MUC1 transgenic mice. Vaccine, 2000, 19, 158-162.	1.7	26
241	Ex vivo targeting of the macrophage mannose receptor generates anti-tumor CTL responses. Vaccine, 2000, 18, 3174-3184.	1.7	105
242	Definition of MHC-restricted CTL epitopes from non-variable number of tandem repeat sequence of MUC1. Vaccine, 2000, 18, 2059-2071.	1.7	31
243	A Functional Hot Spot for Antigen Recognition in a Superagonist TCR/MHC Complex. Immunity, 2000, 12, 251-261.	6.6	202
244	A Structural Framework for Deciphering the Link Between I-Ag7 and Autoimmune Diabetes. Science, 2000, 288, 505-511.	6.0	245
245	Cytokine Production from Murine CD4 and CD8 Cells After Mannan-MUC1 Immunization. Journal of Interferon and Cytokine Research, 1999, 19, 1373-1379.	0.5	17
246	Mimics and cross reactions of relevance to tumour immunotherapy. Vaccine, 1999, 18, 268-275.	1.7	20
247	Peptide mimics of a tumor antigen induce functional cytotoxic T cells. Nature Biotechnology, 1998, 16, 276-280.	9.4	38
248	MUC1 cross-reactive Galα(l,3)Gal antibodies in humans switch immune responses from cellular to humoral. Nature Medicine, 1998, 4, 315-320.	15.2	93
249	Parameters for using mannan-MUC1 fusion protein to induce cellular immunity. Cancer Immunology, Immunotherapy, 1998, 45, 321-326.	2.0	42
250	Oxidised mannan antigen conjugates preferentially stimulate T1 type immune responses. Veterinary Immunology and Immunopathology, 1998, 63, 185-190.	0.5	22
251	Induction of T1 (cytotoxic lymphocyte) and/or T2 (antibody) responses to a mucin-1 tumour antigen. Vaccine, 1997, 15, 1586-1593.	1.7	41
252	MUC1 peptide epitopes associated with five different H-2 class I molecules. European Journal of Immunology, 1997, 27, 2579-2587.	1.6	65

#	Article	IF	CITATIONS
253	Cell-mediated immune responses to MUC1 fusion protein coupled to mannan. Vaccine, 1996, 14, 930-938.	1.7	120
254	Breast cancer immunotherapy: Current status and future prospects. Immunology and Cell Biology, 1996, 74, 457-464.	1.0	40
255	Anti-peptide monoclonal antibodies to intestinal mucin 3. Journal of Gastroenterology and Hepatology (Australia), 1995, 10, 555-561.	1.4	17
256	Cellular Mucins: Targets for Immunotherapy. Critical Reviews in Immunology, 1994, 14, 293-309.	1.0	103